The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients

Background: Multiple sclerosis (MS) is a disease that affects young people of reproductive age (20-40 years old), predominantly women. Therefore, almost every patient has questions about pregnancy and breastfeeding. Family planning is one of the key issues in the choice of treatment tactics. Despite the growing number of therapeutic options for individualized treatment, it is still a question how to manage women with MS who become pregnant while taking disease-modifying drugs or want to become pregnant after starting this treatment. Conclusions: Women with MS should not be discouraged from pregnancy due to their illness. It is necessary to proactively discuss pregnancy planning with all women with MS of childbearing age. Based on available data, interferon beta and glatiramer acetate appear to be most suitable for use up until the time of confirmed pregnancy. A large amount of data (more than 1000 cases) obtained from registries shows that use of interferon beta before conception and during pregnancy suggests no evidence of increase in the rate of congenital anomalies or spontaneous abortions. For women with persistent high disease activity, pulsed immune reconstitution therapy gives additional opportunity for family planning after the last dose. The choice between available options for pulsed immune reconstitution therapy should be based on efficacy balanced against the risks.

Download Full-text

Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway

Scientific Reports ◽

10.1038/s41598-017-16828-x ◽

2017 ◽

Vol 7 (1) ◽

Cited By ~ 2

Author(s):

Isaac Hurtado-Guerrero ◽

Maria Jesus Pinto-Medel ◽

Patricia Urbaneja ◽

Jose Luis Rodriguez-Bada ◽

Jesús Ortega-Pinazo ◽

...

Keyword(s):

Multiple Sclerosis ◽

Signaling Pathway ◽

Interferon Beta ◽

Cross Reactivity ◽

Stat Signaling ◽

Multiple Sclerosis Patients

Download Full-text

Disease progression among multiple sclerosis patients before and during a disease-modifying drug program: a longitudinal population-based evaluation

Multiple Sclerosis Journal ◽

10.1177/1352458509350307 ◽

2009 ◽

Vol 15 (11) ◽

pp. 1286-1294 ◽

Cited By ~ 22

Author(s):

PJ Veugelers ◽

JD Fisk ◽

MG Brown ◽

K. Stadnyk ◽

IS Sketris ◽

...

Keyword(s):

Multiple Sclerosis ◽

Disease Progression ◽

Program Effectiveness ◽

Population Based ◽

Eligibility Criteria ◽

Disease Modifying Drugs ◽

Regression Methods ◽

Disease Modifying ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Randomized controlled trials have demonstrated the efficacy of disease-modifying drugs (DMDs) in persons with relapsing—remitting multiple sclerosis (MS) and secondary progressive MS with superimposed relapses. However, these brief studies of selected patients have focused mainly on reducing attacks and must be complemented by evaluations in ‘realworld’ clinical settings to establish the effectiveness of DMD programs in slowing disease progression and to inform health policy and program decision-making. We assessed the effectiveness of DMDs as administered in a comprehensive publicly funded drug insurance program that provides DMDs to a geographically defined population of MS patients who meet specific eligibility criteria. Data from 1752 MS patients (10,312 assessments) seen between 1980 and 2004 at a regional MS Clinic serving the entire population of Nova Scotia, Canada were analysed. Using survival methods we observed a statistically significant reduction in disease progression to specific Expanded Disability Status Scale endpoints following the introduction of this program. Subgroup analyses of patients eligible for treatment using hierarchical linear regression methods also suggested that disease progression was slowed in patients treated with the first DMD prescribed. These findings provide evidence supporting DMD program effectiveness that can be used to inform the broader implementation of such programs.

Download Full-text

CPC-033 Comparing Effectiveness of First-Line Disease Modifying Drugs in Relapsing-Remitting Multiple Sclerosis Patients

European Journal of Hospital Pharmacy ◽

10.1136/ejhpharm-2013-000276.490 ◽

2013 ◽

Vol 20 (Suppl 1) ◽

pp. A177.2-A177

Author(s):

H Esteban-Cartelle ◽

E Espino-Paisan ◽

C Crespo-Diz ◽

T Rodríguez-Jato ◽

P Suarez Artime

Keyword(s):

Multiple Sclerosis ◽

First Line ◽

Disease Modifying Drugs ◽

Relapsing Remitting ◽

Disease Modifying ◽

Remitting Multiple Sclerosis ◽

Multiple Sclerosis Patients ◽

Relapsing Remitting Multiple Sclerosis

Download Full-text

Adherence to Multiple Sclerosis Disease-Modifying Therapies in Ontario is Low

Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques ◽

10.1017/s0317167100011823 ◽

2011 ◽

Vol 38 (3) ◽

pp. 429-433 ◽

Cited By ~ 42

Author(s):

Janice Wong ◽

Tara Gomes ◽

Muhammad Mamdani ◽

Michael Manno ◽

Paul W. O'Connor

Keyword(s):

Multiple Sclerosis ◽

Glatiramer Acetate ◽

Interferon Beta ◽

Patient Adherence ◽

Disease Modifying Drugs ◽

Drug Plan ◽

Persistence Rates ◽

Disease Modifying ◽

Public Drug

Background/Objective:Differences in patient adherence to various disease-modifying drugs (DMDs) in the treatment of multiple sclerosis (MS) are not well understood. The goal of this study was to evaluate adherence of adult MS patients in Ontario with public drug plan coverage to various DMDs: intramuscular interferon beta-1a (i.m. IFNβ-1a, Avonex), subcutaneous interferon beta-1a (s.c. IFNβ-1a, Rebif), subcutaneous interferon beta-1b (IFNβ-1b, Betaseron) or glatiramer acetate (Copaxone).Methods:In this retrospective cohort study, Ontario Public Drug Plan beneficiaries aged 15 or older who were newly treated with i.m. IFNβ-1a, s.c. IFNβ-1a, IFNβ-1b or glatiramer acetate between April 2006 and March 2008 were followed forward until treatment discontinuation, switch to another DMD or a maximum two year follow-up period. Cumulative persistence rates were analyzed by the Kaplan-Meier method. The proportion of patients reaching the study endpoints after the two year follow-up period was also calculated.Results:Cumulative persistence rates for all four DMDs were similar over time (p=0.80), ranging from 73.6-79.1% at six months, 59.1-63.1% at one year and 41.5-47.4% at two years. After two years, the proportion of patients who had discontinued treatment, switched to another DMD or died was similar among DMDs (p=0.79, Fisher's exact test). Switching between DMD types was low and occurred in 3.4-6.5% of new DMD users.Conclusions:Adherence to DMDs in adult MS patients in Ontario is poor, which is consistent with previously reported adherence rates to MS DMDs in other regions. No significant differences in adherence exist between the DMDs evaluated in this study.

Download Full-text

PND23 PREVALENCE OF TREATMENT GAPS IN MULTIPLE SCLEROSIS PATIENTS RECEIVING DISEASE-MODIFYING DRUGS: FINDINGS FROM A NATIONAL MANAGED CARE DATABASE

Value in Health ◽

10.1016/s1098-3015(10)74030-4 ◽

2009 ◽

Vol 12 (3) ◽

pp. A194

Author(s):

C Fincher ◽

C Kozma ◽

DM Meletiche ◽

M Dickson

Keyword(s):

Multiple Sclerosis ◽

Managed Care ◽

Disease Modifying Drugs ◽

Treatment Gaps ◽

Disease Modifying ◽

Multiple Sclerosis Patients ◽

Care Database

Download Full-text

Interferon-beta exposure during first trimester is safe in women with multiple sclerosis—A prospective cohort study from the German Multiple Sclerosis and Pregnancy Registry

Multiple Sclerosis Journal ◽

10.1177/1352458516634872 ◽

2016 ◽

Vol 22 (6) ◽

pp. 801-809 ◽

Cited By ~ 64

Author(s):

Sandra Thiel ◽

Annette Langer-Gould ◽

Milena Rockhoff ◽

Aiden Haghikia ◽

Annette Queisser-Wahrendorf ◽

...

Keyword(s):

Multiple Sclerosis ◽

Birth Weight ◽

Preterm Birth ◽

Pregnancy Outcomes ◽

Interferon Beta ◽

First Trimester ◽

Disease Modifying Therapies ◽

Disease Modifying ◽

Multiple Sclerosis Patients ◽

Pregnancy Registry

Background: Available data suggest that pregnancy exposure to interferon-beta might result in lower mean birth weight and preterm birth. Objective: To determine the effect of interferon-beta exposure during pregnancy on pregnancy outcomes in multiple sclerosis patients. Methods: We compared the pregnancy outcomes of women exposed to interferon-beta with pregnancies unexposed to disease-modifying therapies. Women were enrolled into the German Multiple Sclerosis and Pregnancy Registry. A standardized questionnaire was administered during pregnancy and postpartum. Detailed information on course of multiple sclerosis and pregnancy, concomitant medications, delivery, and outcome of pregnancy was obtained. Results: We collected data on 251 pregnancies exposed to interferon-beta and 194 unexposed to disease-modifying therapies. In all, 246 (98.01%) women discontinued interferon-beta treatment during first trimester. No differences regarding mean birth weight (exposed: 3272.28 ± 563.61 g; unexposed: 3267.46 ± 609.81 g), mean birth length (exposed: 50.73 ± 3.30 cm; unexposed: 50.88 ± 3.45 cm), preterm birth ( p = 0.187), spontaneous abortion ( p = 0.304), and congenital anomalies ( p = 0.197) were observed between the two groups. Conclusions: Interferon-beta exposure during early pregnancy does not influence the mean birth weight, risk of preterm birth, or other adverse pregnancy outcomes. Our study provides further reassurance that interferon-beta treatment can be safely continued up until women become pregnant.

Download Full-text